In addition to the severity of HCV-induced liver fibrosis and cirrhosis, we evaluated the impact of the MIF promoter polymorphisms on the prevalence of HCC in patients with HCV-induced liver disease. This evidence concerns the gene MIF and hepatocellular carcinoma.